Earnings Releases·Nov 4, 2026, 4:12 PM ET

Sight Sciences — Third Quarter 2026 Earnings Summary

Total revenue reached a record $24.9 million, up 25% year-over-year, driven by a 45% sequential increase in Interventional Dry Eye (IDE) revenue to $3.9 million and a 7% year-over-year rise in Interventional Glaucoma (IG) revenue to $21.0 million.
Full-year 2026 revenue guidance was raised to $92 million–$93 million (19%–20% growth) from the previous $88 million–$92 million range, with IDE guidance increased to approximately $12 million from $9 million–$11 million.
Net loss narrowed 17% year-over-year to $6.8 million ($0.12 per share), supported by a 74% reduction in cash usage to $2.4 million and improved IDE gross margins expanding to 79% from 38%.
Strategic momentum includes the launch of the OMNI® Ultra Surgical System, a 12% increase in IG active customers to 1,253, and a 344% surge in IDE lid treatment units sold to 4,581.